Axcan Pharma Inc - Report of Foreign Issuer (6-K)
January 14 2008 - 11:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the
month of January, 2008
Commission
File Number 0-30860
Axcan Pharma Inc.
(Exact
Name of Registrant)
597,
boul, Laurier, Mont-Saint-Hilaire (Québec), Canada J3H 6C4
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
o
Form 40-F
x
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as
permitted by
Regulation
S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as
permitted by
Regulation
S-T Rule 101(b)(7):
Indicate by check mark
whether the registrant by furnishing the information contained in this Form is
also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes
o
No
x
If
Yes is marked, indicate the file number assigned to the registrant in
connection with Rule 12g3-2(b):
82-
EXHIBITS
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
January 14, 2008
Letter to Shareholders of Axcan Pharma Inc..
|
|
|
|
|
|
99.2
|
|
December 20, 2007
press release entitled Axcan Pharma Inc. Obtains Interim Order for Proposed
Arrangement and Announces Date of Special Shareholder Meeting.
|
|
|
|
|
|
99.3
|
|
January 10, 2008
press release entitled Axcan and TPG Capital Receive Antitrust Clearances in
Connection with the Proposed Acquisition.
|
|
|
|
|
|
99.4
|
|
January 10, 2008
press release entitled ISS, Proxy Governance, Inc. and Glass,
Lewis & Co. Recommend Shareholders Vote For the Proposed
Acquisition of Axcan Pharma by an Affiliate of TPG Capital.
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Date: January 14,
2008
|
By:
|
/s/ Richard Tarte
|
|
Name:
|
Richard Tarte
|
|
Title:
|
Vice President, Corporate
Development
|
|
|
and General Counsel
|
3
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Jan 2024 to Jan 2025